A Double Blind, Randomized, Placebo-controlled Study to Evaluate, Safety, Tolerability, Efficacy and Preliminary Dose-response of BAF312 in Patients With Active Dermatomyositis.

Trial Profile

A Double Blind, Randomized, Placebo-controlled Study to Evaluate, Safety, Tolerability, Efficacy and Preliminary Dose-response of BAF312 in Patients With Active Dermatomyositis.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Siponimod (Primary)
  • Indications Dermatomyositis
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 04 Apr 2016 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 25 Jan 2016 Planned end date changed from 1 Apr 2017 to 1 Feb 2016, as reported by ClinicalTrials.gov.
    • 25 Jan 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Feb 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top